BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Niparuck P, Chuncharunee S, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasri N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T; Thai Lymphoma Study Group. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol 2019;37:578-85. [PMID: 31702065 DOI: 10.1002/hon.2687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Niparuck P, Chuncharunee S, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasi N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T. Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group. Leuk Lymphoma 2020;61:2614-21. [PMID: 32573294 DOI: 10.1080/10428194.2020.1780586] [Reference Citation Analysis]
2 Desmirean M, Richlitzki C, Pasca S, Teodorescu P, Petrushev B, Rauch S, Steinheber J, Iluta S, Liu J, Dima D, Grewal R, Ma W, Qian L, Tomuleasa C. Correlation between the prevalence of T-cell lymphomas and alcohol consumption. Med Pharm Rep 2021;94:298-306. [PMID: 34430851 DOI: 10.15386/mpr-1777] [Reference Citation Analysis]
3 Hammel P, Carrier E, Carney M, Eisner M, Fleming T. A novel event-free survival endpoint in locally advanced pancreatic cancer. Ther Adv Med Oncol 2021;13:17588359211059586. [PMID: 34868352 DOI: 10.1177/17588359211059586] [Reference Citation Analysis]
4 Assouline S, Wiesinger A, Spooner C, Jovanović J, Schlueter M. Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103711] [Reference Citation Analysis]
5 Fujimoto A, Anzai T, Fukuda T, Uchida N, Ohta T, Mori T, Sawa M, Yoshioka S, Miyamoto T, Uchiyama H, Katayama Y, Matsuoka KI, Shiratori S, Nakazawa H, Kanda J, Ichinohe T, Atsuta Y, Fujita N, Kondo E, Suzuki R. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. Blood Adv 2021;5:1412-24. [PMID: 33666656 DOI: 10.1182/bloodadvances.2020003735] [Reference Citation Analysis]
6 Yamasaki S, Iida H, Yoshida I, Komeno T, Sawamura M, Matsumoto M, Sekiguchi N, Hishita T, Sunami K, Shimomura T, Takatsuki H, Yoshida S, Otsuka M, Kato T, Kuroda Y, Ooyama T, Suzuki Y, Ohshima K, Nagai H, Iwasaki H. Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan. Leuk Lymphoma 2021;62:819-27. [PMID: 33167741 DOI: 10.1080/10428194.2020.1845336] [Reference Citation Analysis]
7 Suzuki Y, Yano T, Suehiro Y, Iwasaki H, Hidaka M, Otsuka M, Sunami K, Ikeda H, Sawamura M, Ito T, Iida H, Nagai H. Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma. Int J Hematol 2020;112:817-24. [PMID: 32886278 DOI: 10.1007/s12185-020-02987-7] [Reference Citation Analysis]
8 Chen H, Qin Y, Yang J, Liu P, Zhang C, He X, Zhou S, Yang S, Gui L, Zhou L, Sun Y, Shi Y. Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. Ann Hematol 2020;99:2847-57. [PMID: 32712792 DOI: 10.1007/s00277-020-04195-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]